Board of directors

Peter Verhaeghe


Chairman of the board

Read more

Peter Verhaeghe

Chairman of the board

Peter Verhaeghe earned his degree in Law from the University of Leuven in 1981, where he graduated magna cum laude. From 1981 to 1983, he was an assistant professor of tax law at the University of Leuven. He earned his LL.M. at Harvard Law School in 1984. He is the managing partner of the corporate finance law and tax law firm VVGB Advocaten - Avocats. He specializes in mergers and acquisitions and corporate finance transactions, with special emphasis on corporate tax, corporate finance and banking law issues. Currently, he is president of the board of directors of Merisant France SAS, a member of the management board of Merisant Company 2 sàrl and a member of the board of CzechPak Manufacturing s.r.o. In the last five years he was the chairman of PharmaNeuroBoost NV, member of the board of Biocartis SA, member of the board of Fujirebio Europe (formerly Innogenetics NV), member of the board of KBC Private Equity Biotech NV and subsequently liquidator in charge of KBC Private Equity Biotech NV. He is currently lead counsel to a number ofBelgian, Dutch and Swiss biotech and diagnostics companies.

Don deBethizy

Dr
Non-executive Director

Read more

Don deBethizy

Dr, Non-executive Director

J. Donald (Don) deBethizy has 30 years of experience in research and development, financial, business and operating management in the biotechnology and consumer products industry. Don is currently President of White City Consulting ApS in Denmark. He served as President and CEO of Santaris Pharma A/S, Denmark and USA until September 2014 when the Company was sold to Roche. He served as Executive Chairman of the Danish biotech Contera Pharma until it was sold to Bukwang Pharma in November 2014. Don was co-founder and CEO (for 12 years) of Targacept, Inc., a public US biotechnology company listed on NASDAQ. He currently serves on the supervisory boards of Newron Pharmaceuticals SPA (NWRN.SW), Serendex Pharmaceuticals A/S (SENDEX:NO), Noxxon Pharma AG and Rigontec GmbH. In recent years, he served on the supervisory boards of LigoCyte Pharma, Enbiotix and Biosource. He holds MS and PhD degrees in toxicology from Utah State University and a BS in biology from the University of Maryland. He completed a postdoctoral fellowship at the Chemical Industry Institute of Toxicology at Research Triangle Park, NC, and is a Diplomat of the American Board of Toxicology. Don has held adjunct appointments at Wake Forest University Babcock School of Management, Wake Forest University School of Medicine and Duke University.

Pamela M. Klein

Dr
Advisor to the Board of Directors

Read more

Pamela M. Klein

Dr, Advisor to the Board of Directors

Pam Klein is Principal of PMK BioResearch offering strategic consulting in oncology drug development to corporate boards, management teams and the investment community. Pam is a member of Scientific Advisor Boards ranging from early start-ups to more established companies with commercial assets. She was Chief Medical Officer of Intellikine (acquired by Millennium/Takeda), where she built the development organization bringing their early compounds from lab to IND and into the clinic, and has served as acting CMO for multiple oncology companies. Prior to this, Pam was at Genentech holding positions of increasing responsibility, lastly as Vice President and Development, where she led the development of several franchises including the HER Family of compounds, the Apoptosis Franchise and the Hematology programs. Prior to Genentech, she was at The National Cancer Institute, where she built, obtained funding and ran the NCI-Navy Breast Center, focusing research on developing surrogate markers of cancer risk, disease activity and predictive markers. Pam earned her MD from Stritch School of Medicine, Loyola University Chicago and completed her internal medicine training at Cedar-Sinai receiving the Leo Rigler Award for Resident of the Year, and the Ben Newman Award for Most Humanistic Physician. She did a Medical Oncology Fellowship at the NCI serving as Chief Fellow and then completed an advanced fellowship in Cancer Genetics.

John de Koning

Dr
Non-executive Director

Read more

John de Koning

Dr, Non-executive Director

John de Koning is a partner at LSP (Life Sciences Partners), one of Europe’s leading investors in the healthcare sector. In addition to argenx, John de Koning serves on the boards of Merus, eTheRNA and G-Therapeutics. Previously, he also served on the Supervisory Boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a Non-Executive director on the boards of Pronota (now MyCartis) and Innovative Biosensors Inc. Prior to joining LSP in 2006, Dr. de Koning was the Managing Director of Semaia Pharmaceuticals (acquired by Hybrigenics), a company targeting the development of innovative drugs for various types of cancers and for diabetes. Previously, he was a senior researcher within several prestigious medical research labs and worked with, among others,  Prof. Hans Clevers, Prof. Bob Löwenberg and Prof. Allan Balmain. Dr. de Koning has a Master’s degree in Medical Biology from the University of Utrecht and a PhD in Oncology from the Erasmus University Rotterdam. After obtaining his PhD, he received a prestigious fellowship from the Dutch Cancer Society to work at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. His results were published in numerous leading scientific journals, including Nature Genetics. 

 
David L. Lacey

Dr
Non-executive Director

Read more

David L. Lacey

Dr, Non-executive Director

David Lacey received both his undergraduate and medical degrees from the University of Colorado and has his board certification in anatomic pathology. He was on the faculty at Washington University in St. Louis, MI, USA following the completion of his training. He joined Amgen in 1994 where during the last five years of his tenure he assumed the head of Discovery Research (> 1200 FTEs) . At any given time there were over 100 actively managed preclinical projects across four therapeutic areas: hematology/oncology, inflammation, metabolic disorders and neuroscience. Scientifically, he played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen which led to the development of the anti-RANKL human mAb denosumab, a blockbuster for both osteoporosis (Prolia) and cancer-related bone diseases (XGEVA). Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product and the 2010 Scrip award for best new drug. Following his retirement in 2011, he has continued to be active in the biopharmaceutical industry. His current activities include advising academic institutions, biotechnology companies and venture capital firms. In addition to argenx , he is a Non-Executive Director of Inbiomotion SL.

Werner Lanthaler

Dr
Non-executive Director

Read more

Werner Lanthaler

Dr, Non-executive Director

Werner Lanthaler is currently Chief Executive Officer of Evotec (Frankfurt Stock Exchange: EVT), a role he took in March 2009. Under his leadership, Evotec has become one of the leading drug discovery research organizations globally. Before that, he spent nine years as Chief Financial Officer at Intercell AG (2000-2009). During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine and antibody player. Dr. Lanthaler played a pivotal role in many of the company’s major corporate milestones including the product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering in 2005. From 1998 to 2000, Dr. Lanthaler served as director of the Federation of Austrian Industry, and from 1995 to 1998 as senior management consultant at the consulting firm McKinsey & Company. He holds a doctorate in Business Administration from Vienna University of Economics and Business, earned a Master’s degree from Harvard University and holds a degree in Psychology. In recent years Dr. Lanthaler served on the supervisory boards of Bioxell SpA and Pantec Biosolutions.

Tim Van Hauwermeiren

MSc, EMBA
Chief Executive Officer

Read more

Tim Van Hauwermeiren

MSc, EMBA, Chief Executive Officer

Tim Van Hauwermeiren is co-founder and CEO of argenx NV. He has more than 20 years of general management and business development experience across the life sciences and fast moving consumer goods sectors.

At argenx NV and Ablynx NV he was involved in raising appr. EUR250 million, including 2 successful Euronext IPO’s, and in the deal making and alliance management with leading pharma companies including P&G Pharma, Novartis, Wyeth, Boehringer Ingelheim, Merck Serono, Eli Lilly, Shire, Bayer and LEO Pharma. Prior to joining the life sciences sector in 2003, he held various management positions with the Procter & Gamble Company in R&D and Business Development, where he conceived and developed several new products. Among those was a PUR® drinking water innovation which won the United Nations ICC World Business Award in 2004.

Tim Van Hauwermeiren holds a Master of Science in Bio-engineering from the University of Gent (Belgium) and received general management training at INSEAD (F) and The Vlerick School of Management (Executive MBA, Belgium). 

Eric Castaldi


Chief Financial Officer

Read more

Eric Castaldi

Chief Financial Officer

Eric Castaldi has 28 years of international financial executive management experience, including 19 years in the bio-pharmaceutical industry. Before joining argenx, he was Chief Financial Officer from 1998 to 2013 at Nicox, a Euronext-listed Biotech company. At Nicox, he was a member of the Executive committee and participated in all the financings of the company since its IPO in November 1999. From 2008 to 2012 he also served as non-executive board member and chairman of the audit committee of Hybrigenics a French biopharmaceutical company specialized in oncology and listed on Euronext.

Prior to this he was Chief Financial Officer and member of the executive committee at Safety Kleen SA, a US-based environmental waste company, where he was responsible for operations in France and Belgium. From 1989 through 1997, he was Chief Financial Officer in charge of French and German operations and member of the executive committee, at My Kinda Town PLC  a European leisure company. During that period, he was involved in the May 1994 flotation of that company on the London Stock Exchange. From 1986 through 1989, he was employed as financial analyst at the Research and Development Centre, located in Sophia Antipolis, of Cordis Corporation, a US-based company specialized in bio-surgical instrumentation.

He graduated in Finance, Accountancy and Administration from the University of Nice in 1986.